12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Indacaterol/mometasone furoate: Development discontinued

Novartis disclosed in its 4Q10 earnings that it discontinued development of QMF149 in the U.S. for COPD and asthma, but declined to specify the reason. The compound is in Phase II testing for...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >